Knight Therapeutics Valuation
| KHTRF Stock | USD 3.73 0.07 1.84% |
At this time, the firm appears to be undervalued. Knight Therapeutics secures a last-minute Real Value of $3.92 per share. The latest price of the firm is $3.73. Our model forecasts the value of Knight Therapeutics from analyzing the firm fundamentals such as Profit Margin of (0.09) %, return on equity of -0.0266, and Current Valuation of 354.32 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Knight Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Knight Therapeutics is based on 3 months time horizon. Increasing Knight Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Knight pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Knight Therapeutics. Since Knight Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Knight Pink Sheet. However, Knight Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.73 | Real 3.92 | Hype 3.73 |
The real value of Knight Pink Sheet, also known as its intrinsic value, is the underlying worth of Knight Therapeutics Company, which is reflected in its stock price. It is based on Knight Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Knight Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Knight Therapeutics helps investors to forecast how Knight pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Knight Therapeutics more accurately as focusing exclusively on Knight Therapeutics' fundamentals will not take into account other important factors: Knight Therapeutics Total Value Analysis
Knight Therapeutics is now projected to have takeover price of 354.32 M with market capitalization of 444.73 M, debt of 9.27 M, and cash on hands of 147.08 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Knight Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
354.32 M | 444.73 M | 9.27 M | 147.08 M |
Knight Therapeutics Investor Information
About 31.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Knight Therapeutics recorded a loss per share of 0.04. The entity had not issued any dividends in recent years. Based on the key indicators related to Knight Therapeutics' liquidity, profitability, solvency, and operating efficiency, Knight Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Knight Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Knight Therapeutics has an asset utilization ratio of 24.55 percent. This implies that the Company is making $0.25 for each dollar of assets. An increasing asset utilization means that Knight Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Knight Therapeutics Ownership Allocation
Knight Therapeutics maintains a total of 113.96 Million outstanding shares. Knight Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Knight Therapeutics Profitability Analysis
The company reported the revenue of 243.48 M. Net Income was 15.68 M with profit before overhead, payroll, taxes, and interest of 115.41 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Knight Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Knight Therapeutics and how it compares across the competition.
About Knight Therapeutics Valuation
The pink sheet valuation mechanism determines Knight Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Knight Therapeutics. We calculate exposure to Knight Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Knight Therapeutics's related companies.Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada. Knight Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 660 people.
8 Steps to conduct Knight Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Knight Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Knight Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Knight Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Knight Therapeutics' revenue streams: Identify Knight Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Knight Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Knight Therapeutics' growth potential: Evaluate Knight Therapeutics' management, business model, and growth potential.
- Determine Knight Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Knight Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Knight Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Knight Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 117.8 M | |
| Quarterly Earnings Growth Y O Y | -0.913 | |
| Forward Price Earnings | 14.6413 | |
| Retained Earnings | 191.6 M |
Complementary Tools for Knight Pink Sheet analysis
When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |